Drug Approval | June 27, 2023
USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
The company will also share results in two additional posters for deuruxolitinib
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Subscribe To Our Newsletter & Stay Updated
